Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject,1 several new abuse-deterrent opioid formulations (Table) have been approved by the FDA,2,3 including an oxycodone tablet formulation (Roxybond – Inspirion) that is the first immediate-release opioid product FDA-approved to include claims of abuse deterrence in its labeling.4 No opioid formulation prevents consumption of a large number of intact dosage units, the most common method of abuse. Abuse-deterrent formulations have one or more properties that make their intentional nontherapeutic use more difficult, less attractive, or less rewarding.5
Abuse-Deterrent Opioids. JAMA. 2018;319(19):2036–2037. doi:10.1001/jama.2018.4996
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: